Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Lenz Therapeutics
LENZ · NASDAQ · Biological Products, (No Diagnostic Substances)
Lenz Therapeutics (LENZ) · oqro.io/stocks/LENZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Traded Jun 10, 2025 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −89.4% · S&P 500 +14.4% · to Nov 20
A major shareholder of Lenz Therapeutics sold $10.2M of Lenz Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
The CEO of Lenz Therapeutics paid $251K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month. Shares held went up 57% with this purchase.
The CFO of Lenz Therapeutics paid $64K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month. Shares held went up 139% with this purchase.
A Lenz Therapeutics director paid $50K out of pocket for Lenz Therapeutics shares. 2 other people at Lenz Therapeutics bought some too, in the same month.
A Lenz Therapeutics director paid $239K out of pocket for Lenz Therapeutics shares. 1 other person at Lenz Therapeutics bought some too, in the same month.
3 open-market purchases and 3 open-market sales by insiders of LENZ between Feb 22, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 28, 2026.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
RA CAPITAL MANAGEMENT, L.P., Oct 29, 2026, about $360K. Sold 1 day after the company's previous earnings release on 2026-10-28Form 4
RA CAPITAL MANAGEMENT, L.P., Oct 29, 2026, about $1.52M. Sold 1 day after the company's previous earnings release on 2026-10-28Form 4
RA CAPITAL MANAGEMENT, L.P., Oct 29, 2026, about $7.26M. Sold 1 day after the company's previous earnings release on 2026-10-28Form 4
Evert B. Schimmelpennink, President, CEO and Secretary, Mar 27, 2026, about $251K. Bought 3 days after the company's previous earnings release on 2026-03-24Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
Jeffrey P. George, Director, Mar 27, 2026, about $50K. Bought 3 days after the company's previous earnings release on 2026-03-24
Daniel R. Chevallard, Chief Financial Officer, Mar 27, 2026, about $64K. Bought 3 days after the company's previous earnings release on 2026-03-24Form 4